Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
Active, not recruiting · NCT04685590 · Registry updated 2026-04-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study | Alzheimer Disease, Early Onset, Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Mild Cognitive Impairment, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 2 | 2026-04-01 | NCT04685590 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The University of Texas Health Science Center at San Antonio | 127 |
| Wake Forest University Health Sciences | 284 |
| Washington University School of Medicine | 475 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hospital Clínic de Barcelona Site | Barcelona | Spain | 1 |
| Wake Forest Health Sciences | Winston-Salem | United States | 5 |